ERBB2 and breast cancer: In conclusion, due to a larger proportion, less clinical heterogeneity, better prognosis, and less susceptibility to risk factors, HER2‐low BC should be suggested as a potentially independent subtype of BC from traditionally HER2‐negative BC and should deserve more attention than HER2‐zero BC, especially in HR‐negative BC.